Monoclonal antibodies (mAb) have revolutionised many areas of medicine, particularly research and diagnostics. Murine, human and humanised mAb have all been developed. The most important clinical applications to date have been in the fields of transplantation and oncology. Experimental and limited clinical trials suggest mAb are emerging as a new therapeutic strategy in the critically ill. Antibodies against a variety of bacteria or their products are potentially useful in gram-positive and gram-negative shock. Anti-cytokine and anti-neutrophil adhesion molecule mAb may be effective not only in septic shock but also in other conditions associated with acute inflammation and cytokine release, e.g., acid aspiration, ischaemia/reperfusion injury (myocardial infarction, haemorrhagic shock, aortic aneurysm repair). Antibodies inhibiting neutrophil adhesion may also be efficacious in asthma, pulmonary fibrosis, meningitis and cerebral malaria. The use of these and other mAb in intensive care is an exciting prospect and future clinical studies will determine the extent of their role in the management of the critically ill.
fused with immortal non-antibody-secreting murine myeloma cells to form a hybridoma by a technique termed cell fusion or somatic-cell hybridisation. Following the isolation of hybrid cells, the preferred hybridoma capable of producing the desired antibody was identified and propagated or cloned. This process yielded a perpetually reproducing cell line producing unlimited quantities of mAb of a single immunoglobulin class with identical structure, affinity and specificity for an antigenic determinant ( Figure 1 ).
The relative simplicity and efficiency with which murine mAb can be produced in cell culture or ascitic fluid has stimulated the generation of thousands of antibodies which are used extensively in research and diagnostics. Therapeutic utility has, however, been restricted by potential immunogenicity and less immunogenic human and "humanised" antibodies have therefore been developed. The use of murine mAb in humans is further limited by the fact that murine antibodies only weakly elicit effector functions such as Fc receptor-mediated antibody-dependent cellular cytotoxicity, complement activation and phagocytosis.
Human antibodies
Human mAb can also be produced by cell fusion, albeit with difficulty. Human myeloma cells have a low fusion efficiency, grow poorly and secrete immunoglobulins. Therefore, the resultant hybridoma secretes immunoglobulins coded for by the genes of both the parent myeloma and B-cells, diluting the desired antibody. Moreover, human-human hybridomas secrete mAb at a low rate. 2 Other problems with human mAb production include the relative paucity of circulating B cells producing the desired antibody in the peripheral bloodstream and ethical issues surrounding the deliberate immunisation of humans, although in vitro incubation of B cells and antigen has recently been described. J Consequently, despite being the least immunogenic, advances in human hybridoma technology have been relatively slow, limiting their therapeutic availability.
In an attempt to overcome some of these problems, murine myeloma cells have been fused with human B
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Remove splenocytes ® Cell death lymphocytes to create non-secreting human-mouse heteromyeloma fusion partners which are then fused with human B lymphocytes, producing the desired antibody; such an example is the anti-lipid A monoclonal, HA-lA (see below), produced by the fusion of B cells with a human-mouse heteromyeloma fusion partner. The donor B cells were initially obtained from two lymphoma patients undergoing splenectomy, following deliberate immunisation with heat-inactivated 15 mutant Escherichia coli Olll:B4. 4 An alternative approach to the production of human mAb is the use of the Epstein-Barr virus to transform human B lymphocytes from an immunised donor into an immortal antibody-secreting lymphoblastoid cell line. 5.6 Again, this technique is not without problems, including the generation of unstable cell lines producing limited quantities of IgM antibody and contamination of the cell line with a potentially oncogenic virus. Combining Epstein-Barr-transformed B cells with human-mouse heteromyeloma fusion partners has also been described. 4, 7 Humanised antibodies Molecular biology techniques have generated "humanised" murine mAb which circumvent many of the limitations of human monoclonals and bypass hybridoma technology.8,9 Chimaeric human-mouse mAb have been created by inserting the genetic sequence encoding the antigen-binding site of the immunoglobulin (the mouse variable-region domain) next to the human constant-region, the largest and most antigenic portion of the antibody. The recombinant DNA is then transfected into a murine myeloma cell line and the encoded antibody secreted. 10, 11 These genetically engineered antibodies are less immunogenic than murine monoclonal antibodies, being approximately 66070 human ( Figure 2 ).
The variable region of an antibody is composed of a framework structure into which the hypervariable complementarity-determining regions (CDRs), which directly bind antigen, are embedded. To further reduce immunogenicity from the murine component, CDRgrafted antibodies are produced by inserting only the DNA sequence of the mouse CDR into the human variable framework and constant regions. 12 ,1l The Heavy Chain -s -s--s -s-CHIMAERIC derived antibody contains approximately 90% human DNA sequence, but rate of antibody secretion and binding affinity for the antigen are often reduced compared to the original murine antibody (Table 1) .
Antibody Class

Murine mAb
Chimaeric mAb Alternatively, mAb can now be produced in bacteria, primarily Escherichia coli. The immunoglobulin variable-region gene from human or murine B cells is amplified by the polymerase chain reaction (a method for rapidly amplifying copies of DNA), introduced into the bacteria and the desired antibody secreted. 14, 15 Using this methodology, large quantities of antibody can potentially be generated rapidly, representing a viable alternative in the future to traditional hybridoma methods for human mAb production. 
DIAGNOSTIC APPLICATIONS
The potential application of monoclonal antibody technology is enormous and there has already been a major impact on the investigation, diagnosis and treatment of a variety of diseases. Radioimmunoassays, enzyme-linked immunosorbent assays and immunofluorescence assays employ mAb to detect a diversity of cellular and soluble antigens. Applications include: rapid detection of selected infectious agents (e.g. LRgionella pneumophila, Pneumocystis carinii, human immunodeficiency virus, Aspergillus); 1619 measurement of circulating cytokines; 20 differentiation of T lymphocyte subsets (T 4, T8 etc); 21 and characterisation of lymphoid malignancies and autoimmune diseases. 22 Diagnostically, radioactively labelled mAb can also be utilised to localise deep venous thrombi (anti-fibrin antibodies), abscesses and neoplasms" and to diagnose the presence, timing and extent of acute myocardial injury (anti-myosin antibodies)."
THERAPEUTIC APPLICATIONS
Therapeutically, the most successful mAb application has been in the field of transplant rejection. OKT3, a murine IgG2a mAb to CD3, the T cell marker involved in foreign antigen recognition, has been used since the mid-1980s to immunosuppress and reverse or prevent acute allograft rejection in renal and, more recently, heart, liver and bone marrow transplant patients. 2' . 26 mAb against other molecules putatively involved in acute organ rejection have also been described. Antibodies which target the interleukin-2 (lL-2) receptor of activated lymphocytes 27 and the CD4 and CD7 T cell markers 2H. 29 or interfere with endothelial-leucocyte interaction JlUI have all been administered successfully. These latter antibodies, e.g. anti-CDI 1118 and anti-ICAM-l, are directed against neutrophil and endothelial cell adhesion molecules and are potentially valuable in a number of critical illnesses (see below). Acute graft-versus-host disease has been treated effectively with anti-tumour necrosis factor (TNF) mAb, in addition to anti-neutrophil adhesion and anti-IL-2 receptor mAb. J234
Immunosuppression of the inflammatory response is also important in many other immunologically mediated diseases. mAb which deplete specific T lymphocyte subpopulations have been successfully used in autoimmune and experimental viral myocarditis. J516 Acute Guillain-Barre syndrome has been treated with OKT3, and although disease activity was not modified, antibodies against other T cell subpopulations may subsequently prove beneficial. J7 Certainly, experimental and preliminary clinical studies suggest anti-CD4 mAb which target helperlinducer T cells will play an increasingly important role in the management of other inflammatory/autoimmune disorders such as rheumatoid arthritis, ]'.]9 systemic vasculitis,40 inflammatory bowel disease,4I myasthenia gravis 42.43 and diabetes mellitus. HA' Anti-HLA class 11 antibodies may also be useful, as they have been shown to prevent the onset of disease in several experimental autoimmune models. 46 Other potentially valuable applications of mAb therapy include:
(i) cancer chemotherapy with tumour-specific antibodies coupled to cytotoxic compounds (e.g. ricin, methotrexate, interferon). mAb have been administered in colorectal, breast and ovarian carcinoma with moderate success, initiating a new era in cancer chemotherapy; 47 (ii) thrombolysis with anti-fibrin antibodies conjugated to recombinant tissue plasminogen activator or urokinase; 48 (iii) inhibition of platelet aggregation with antibodies against the platelet glycoprotein lIb/ilIa receptor which binds fibrinogen; coronary artery occlusion and thrombosis of arterial grafts have both been prevented in vivo with anti-lIb/IlIa mAb; 4950 (iv) antiviral therapy; clinical cytomegalovirus and hepatitis B virus infections have been successfully treated with specific mAb 5u2 and antibodies which neutralise herpes and human immunodeficiency viruses prevent in vitro infection. 5]"
IMMUNOTHERAPY FOR THE CRITICALLY ILL Experimental and clinical studies are now demonstrating the potential role of monoclonal antibody therapy in intensive care. Particularly relevant are three groups of mAb: (1) anti-bacterial, (2) anticytokine and (3) anti-neutrophil adhesion molecule antibodies.
(1) Anti-bacterial antibodies Organism-specific mAb Passive immunisation with antibodies neutralising the toxin responsible for Staphylococcus aureusinduced toxic shock syndrome are highly protective, reducing both organ failure and mortality in vivo. 56 Immunotherapy with mAb against specific serotypes of gram-positive and gram-negative bacteria such as Group B Streptococcus, Neisseria meningitidis, Escherichia coli and Pseudomonas aeruginosa are also efficacious in experimental infections caused by the homologous bacteria (to which the antibody has been developed). '761 Anaesthesia and IlIlensive Care, Vol. 21, No. 6, December, 1993 Despite the potential efficacy of these antibodies, therapy is restricted to bacterial species which possess only a few different serotypes, such as Pseudomonas aeruginosa. Clinical applicability is also limited to microbiologically documented infections. In contrast, mAb which react with a diversity of bacteria or their common structures have a much wider therapeutic utility.
Cross-reactive mAb
Passive immunisation against lipopolysaccharide (LPS), a common component of the outer membrane of gram-negative bacteria, was first described by Freedman in 1959. 62 Subsequent investigators noted that polyc1onal sera against LPS could prevent both the local and generalised Schwartzman reactions and reduce mortality in animals exposed to LPS or gramnegative bacteria. 6370 Many of these early studies also demonstrated crossprotection with antibodies against the toxic inner-core polysaccharide and lipid A region of LPS, structurally similar among different species of gram-negative bacteria. Conversely, antibodies against the outer O-antigen oligosaccharide region, unique to each strain of bacteria, although providing greater protection, were serotype-specific.
Anti-core polyc1onal sera raised against the J5 rough mutant of E. coli 0111:B4, which lacks the outer O-antigen, were subsequently reported to reduce mortality in patients with established gram-negative bacteraemia, especially with shock and to prevent the development of shock, but not gram-negative infection, in high-risk surgical patients when administered prophylactically.7I,72 However, contradictory results have been reported. J 5 antisera have failed to prevent death in a variety of experimental gram-negative infections and, in children with fulminant meningococcaemia, a beneficial effect was not observed. 71, 74 Therapeutic and prophylactic purified anti-core immunoglobulin preparations have also been shown to be no more protective than standard intravenous IgG immunoglobulin in patients with gram-negative septic shock. 75, 76 More recently, mAb have overcome the inherent problems of polyc1onal therapy (availability of donors, lack of standardisation, risk of disease transmission). Murine and "human" anti-core antibodies demonstrate prophylactic and therapeutic efficacy in lethal models of gram-negative sepsis. 4 ,7781 However, as with polyc1onal sera, immunoprotection has not always been reproducible or cross-protective. Using similar animal models, anti-J5 mAb have not improved survival following lethal challenge with either heterologous Anaesthesia and Intensive Care. Vol. 21 . No. 6. December. 1993 gram-negative bacteria or J5, the organism to which the mAb is raised. 7y . Xl . 83 Furthermore, prophylactic anti-core mAb provide negligible protection in endotoxin-induced ovine acute lung injury (anti-J5) and inconsistently fail to inhibit LPS-induced cytokine secretion. <4"' Why anti-core antibodies do not consistently demonstrate in vivo protection is strongly debated, but could relate to masking of the inner core region in smooth bacteria possessing the O-antigen and/or intra-and inter-species variability in the chemical structure of the core region. 88 Certainly, broad cross-reactivity and the mechanism of protection of core-specific mAb are not established. 89 Precise binding to bacterial antigenic determinants (epitopes) is also not resolved and nonspecific binding to hydrophobic substances has been demonstrated with an "anti-lipid A" mAb (HA-lA), raising doubts about true epitope specificity of anticore antibodies. YO. Y] Discrepant experimental data might also be explained by differences in immunoglobulin subtype (lgM versus IgG}Y2Y4 and study methodology or LPS contamination of prophylactic antibody, thereby inducing tolerance to subsequent bacterial or LPS challenge. 95 Two major randomised, double-blind, placebocontrolled studies with a murine (E5) or mouse-human heterohybridoma (HA-lA) anti-J5 IgM mAb in patients with suspected gram-negative sepsis have demonstrated resolution of organ failure and reduced hospital mortality: (i) in the E5 study, in bacteraemic and nonbacteraemic patients, but only if shock was not present 96 (ii) in the HA-lA study, with cUlture-positive gramnegative bacteraemia, especially with shock. 97 In the HA-lA study shock was defined as hypotension unresponsive to fluid challenge and/or inotrope dependency, whilst in the E5 study shock was defined as hypotension refractory to fluids and inotropes. Nevertheless, even allowing for this difference, the subgroups benefiting remain contradictory. Notably, overall survival was not improved in either study.
E5 patients received two doses of antibody, whilst HA-lA patients received one dose only, despite similar half-lives of less than 20 hours. Imbalances in riskstratification and antibiotic therapy also exist in the HA-lA study. The Apache II score and percentage of patients with organ failure tended to be higher in the placebo group (especially in the endotoxaemic subgroup), whilst adequate antibiotic therapy was greater in patients receiving HA-lA. When only gram-negative bacteraemic patients receiving adequate antimicrobial therapy are analysed, there was no difference in mortality between placebo and treatment groups. 98 A trend towards increased mortality in non-gram-negative bacteraemic patients was also observed.
Despite the lack of consistent experimental data, and on the basis of "established clinical efficacy", HA-lA was approved by the Federal Drug Administration in the United States for use in patients with gram-negative sepsis and septic shock. Recently, the mAb has been withdrawn from the world market following interim analysis of a repeat study (Centocor HA-lA Efficacy in Septic Shock, or CHESS, trial) which has suggested an increased mortality in the subgroup of patients who were not gram-negative bacteraemic (Eli Lilly, personal communication). Data concerning the subgroup of patients who were gram-negative bacteraemic are not currently available. Pending ongoing analysis, the CHESS trial has been suspended, except in the subgroup of patients with fulminant meningococcaemia. Furthermore, a subsequent larger study of E5 mAb has failed to reconfirm a reduction in mortality in patients with gram-negative sepsis without shock: instead, there was only a trend towards a beneficial effect in patients with end-organ failure. 100 The efficacy of anti-core mAb has therefore not been established either experimentally or clinically and further studies will be required before their role in the treatment of gram-negative sepsis can be established. The place of therapy in at-risk patients also requires evaluation, although a prophylactic study with multiple dosing of HA-lA has commenced. 99 
(2) Anti-cytokine antibodies
Anti-TNF antibodies TNF, a macrophage-derived cytokine, is an important mediator of the septic response. Prophylactic immunisation with polyclonal and monoclonal antibodies against TNF prevents the dermal Schwartzman reaction and reduces mortality and multiple organ failure in animal models of gram-negative bacteraemia and septic shock. I(XIIO' Circulating interleukins are also diminished following pre-treatment with anti-TNF mAb in a baboon model of Escherichia coli sepsis. 106 .111-Timing of mAb administration was crucial in the early studies: antibody given two or more hours before challenge affording maximal protection. Subsequent investigators demonstrated that early post-treatment with anti-TNF antibodies improves survival after both gram-positive and gram-negative infection.'OR]]1I Additionally, in a rat model of systemic organ injury, anti-TNF antiserum administered shortly after acid aspiration attenuated lung and systemic organ leukosequestration and oedema. III Efficacy of anti-TNF mAb in sepsis may, however, be limited to selected infections. Zanetti et al. 112 noted that anti-TNF mAb were fully protective after intravenous Escherichia coli, but after intraperitoneal challenge survival was not improved. In contrast, typespecific anti-LPS antibodies were protective in both models. Silva et al. demonstrated minimal benefit with anti-TNF mAb in lethal Pseudomonas aeruginosa bacteraemia, although mortality was significantly reduced in an Escherichia coli model. 110 Combination immunotherapy with other mAb may be more efficacious in sepsis, a combination of anti-TNF and anti-Pseudomonas serotype-specific mAb providing greater protection than either mAb alone in a model of Pseudomonas septic shock. IIJ In two small, uncontrolled studies of patients with gram-positive or gram-negative septic shock, administration of a single dose of a murine IgG, anti-TNF mAb (CBOOO6) improved haemodynamic performance: in a phase I study, hypotension was reversed, with no adverse side-effects (after a single administration), although acute hypotension occurred in one patient on re-administration 10 days after the initial injection. 114 In a study of 10 patients by Vincent et aI., transient improvement in left ventricular function was also noted. 115 No conclusions regarding mortality could be drawn from either study. Clinical trials with murine and chimaeric anti-TNF mAb are underway in Europe and the United States.
Anti-TNF mAb may also be important in the prevention of ischaemia/reperfusion injury. Antisera and mAb against TNF reduce lung permeability and leukosequestration in models of intestinal and liver ischaemia/reperfusion injury preand post-induction of ischaemia. 11611' In studies which simulate the reperfusion injury of abdominal aortic aneurysm surgery, TNF antisera administered after four hours of bilateral hind limb ischaemia also reduce pulmonary oedema, neutrophil sequestration and leukotriene B4 accumulation in bronchoalveolar fluid. 119 
Anti-interleukin mAb
The proinflammatory interleukins IL-I, IL-6 and IL-8 are also considered to be important in the pathogenesis of the septic response. Although, to date, there are no clinical studies establishing the efficacy of anti-interleukin mAb in sepsis, antibodies directed against IL-6 have been shown to be protective in lethal Escherichia coli infection in mice. 120 Antibodies to IL-l reduce neutrophil exudation in experimental meningitis l21 and antibodies targeting the IL-I receptor inhibit LPS-and IL-I-induced acute phase protein synthesis, glucocorticoid release and neutrophil accumulation in vivo. 122 A role for mAb against either IL-I or its receptor in sepsis is also suggested by experimental studies demonstrating the protection afforded by recombinant IL-I receptor antagonists in gram-positive and gramnegative shock.123,124 A multicentre, randomised, double-blind, placebo-controlled phase III clinical trial involving the administration of a recombinant Type I IL-I receptor antagonist to patients with the sepsis syndrome has recently been completed, although the results are not yet published.
Immunotherapy with antibodies which modulate TNF and interleukin activity must, however, be carefully balanced against the protective function of cytokines in acute inflammation and infection. Pretreatment with TNF or IL-I protects animals from subsequent lethal TNF or bacterial challenge and, in models of burn injury combined with an infectious challenge, administration of anti-TNF mAb is associated with increased mortality.125,126 The beneficial effect of these cytokines in host defense against infection is further emphasised by studies which have demonstrated reduced T cell-mediated resistance and survival with anti-TNF or IL-I mAb in lethal models of Listeria monocytogenes, Histoplasmosis capsulatum and Chlamydia trachomatis infection. 127, 129 (
3) Anti-neutrophil adhesion molecule antibodies
Neutrophil adherence to the endothelium depends upon cytokine-induced expression, upregulation and differential binding of 3 families of cell adhesion molecules ( Table 2) :
(i) the beta2 integrin subfamily; composed of three heterodimers with a common beta subunit linked to each of three alpha subunits-COlla/C0l8, COllb/COI8 and COlIc/C0l8. The COl1l18 integrins are located on the surface of neutrophils (ii) intercellular adhesion molecule-l (ICAM-I), ICAM-2 and the recently isolated ICAM-3, which are the endothelial receptors or ligands of the beta2 integrins (iii) the select in family; consisting of three adhesion molecules; L-selectin, which is expressed on neutrophils, and E-selectin and P-selectin, which are located on endothelial cells. In vitro inhibition of adhesion with mAb targeting these adhesion molecules has prompted their use in disease models of acute inflammation and neutrophilmediated endothelial injury.
Ischaemia/reperfusion
Numerous studies have investigated ischaemia/ reperfusion injury with anti-neutrophil adhesion molecule mAb. Administration both before and after the induction of ischaemia is equally protective. In isolated intestinal, skeletal muscle and rabbit ear preparations, mAb directed against the COl8 betasubunit of the COll/COI8 complex attenuate microvascular injury.130132 MAb inhibiting COI8dependent adhesion also diminish myocardial infarct size by up to 50% (anti-COll/18, anti-ICAM-I) and reduce reperfusion-induced spinal cord injury (anti-ICAM_I).133.136 Ischaemic injury is, however, not prevented by anti-ICAM-I antibodies in a multiple cerebral embolism model. 137 In whole-animal models of generalised ischaemia/ reperfusion, pre-and post-treatment with a murine anti-C0l8 antibody (60.3) reduced mortality, fluid requirements and gastrointestinal injury following haemorrhagic shock. 137·138 Acute lung injury was not prevented in these studies. However, mAb against both C0l8 and its endothelial ligand, ICAM-I, are protective in isolated lung models of pulmonary ischaemia/reperfusion, attenuating rises in pulmonary artery pressure and capillary permeability. 139, 140 It is noteworthy that in other models of acute lung injury, anti-COl1l18 and anti-ICAM-I mAb have either failed to inhibit, or only partially inhibited, neutrophil sequestration, leading to controversy about the importance of COl8-dependent versus E-selectindependent pathways of pulmonary neutrophil sequestration. 141·144
Neutrophil-mediated endothelial injury is also important in the pathogenesis of sepsis and multiple organ dysfunction. Immunotherapy with antineutrophil adhesion molecule mAb is supported by recent animal and clinical studies demonstrating increased tissue bound and circulating ELAM-Ilevels in septic shock. 145,146 ICAM-I expression on pulmonary vascular endothelial cells is also stimulated after infusion of TNF and expression of the C0l8 beta subunit on circulating neutrophils is upregulated after the infusion of live bacteria. 145, 147 In patients with traumatic and non-traumatic acute lung injury, COllb expression has been shown to be increased. 148, 149 In models of both gram-negative sepsis and TNFinduced lung injury, pretreatment with mAb against either C0l8 or ICAM-I have attenuated neutropaenia, pulmonary sequestration of neutrophils and increased s. PEAKE pulmonary capillary permeability. "',150,'" Neutrophil emigration into the peritoneum is inhibited by anti-CDl8 antibodies in models of bacterial peritonitis. I •• ,'" Antibodies against CDl8 and CDllb also prevent endotoxin-induced liver damage, although anti-CDlla mAb are ineffective in preventing injury. "3 Improved haemodynamic status with anti-neutrophil adhesion molecule antibodies has not been demonstrated in sepsis. "4 In fact, in a canine model of gramnegative sepsis, antibodies specific for CDlla worsened cardiovascular function and tended to reduce survival. ,,4 A similar effect has been noted in an ovine model of kidney transplant rejection. "5 Contamination of infused mAb with LPS may account for the apparent deleterious effect of CDlla mAb. However, when considering the proposed beneficial effect of these antibodies in sepsis, it should be noted that the CDl8 adhesion complex is also present on macrophages and is important for LPS binding and phagocytosis by macrophages. "6 Inherited deficiency of the CDl8 complex is associated with an increased susceptibility to infection and sepsis and CDllb expression has been shown to be downregulated in patients with infectious complications following severe burns or trauma. 157 Nevertheless, in a study specifically designed to address this issue, prophylactic anti-CDl8 mAb did not increase infectious complications or mortality after appendiceal devascularisation. ,, 8 Anti-adhesion mAb also appear to hold great promise in many other conditions, including: (i) asthma; ICAM-I has been proposed by many investigators to play a pivotal role in airway inflammation. Anti-ICAM-I mAb prevent increased airway inflammation and hyperresponsiveness following cessation of steroid treatment and attenuate eosinophil accumulation and airway hyperresponsiveness in a primate model of antigen-induced asthma; 15"161 (ii) pulmonary fibrosis; circulating ICAM-I levels are elevated in patients with idiopathic pulmonary fibrosis. 16' Antibodies that inhibit neutrophil adhesion via the ICAM-I ligand (anti-CDlla and -CDllb mAb) prevent the development of experimental drug-induced fibrosis; 163 (iii) allograft rejection; ICAM-I levels correlate with rejection and antibodies against both CDlll18 and ICAM-I have been successful in preventing graft rejection; JO,1I (iv) meningitis; antibodies recognising the common CDl8 subunit reduce meningeal inflammation, bacteraemia and mortality in experimental meningitis; 10 .,10' (v) cerebral malaria; late administration of both anti-CDlla and anti-TNF mAb demonstrate efficacy in murine cerebral malaria. In contrast, anti-ICAM-I mAb have been shown to accelerate death. 166 SIDE-EFFECTS Adverse effects following the administration of both human and murine mAb are uncommon. The most common reactions include headache, chills, fever, gastrointestinal symptoms and, occasionally, hypersensitivity reactions and anaphylaxis. Antibodies which react with T lymphocytes to induce immunosuppression are associated with an increased incidence of infections and B-cell neoplasms. Anti-T lymphocytes (e.g. OKT3) can also stimulate T cells and induce the release of cytokines (cytokine release syndrome). Symptoms of the cytokine release syndrome range from flu-like symptoms to pulmonary oedema, aseptic meningitis, shock and cardiac arrest. Nevertheless, the complication of greatest concern is the formation of neutralising human anti-mouse antibodies (HAMA), particularly with repeated administration of mAb. Murine, chimaeric and heteromyeloma mAb can all stimulate a HAMA response. Although this is generally not a life-threatening problem, biological efficacy is reduced with rapid clearance of immune complexes by the reticuloendothelial system.
THE FUTURE
Prospects for the therapeutic use of mAb in intensive care are now unfolding. In addition to the aforementioned antibodies, mAb specific for LPS-binding protein, C5a and tissue factor have been efficacious in models of acute lung injury and sepsis. 167,16' Prophylactic and therapeutic anti-interferon gamma mAb improve survival in models of septic shock and modulate infection after haemorrhagic shock and trauma. 1691'2 Ischaemic liver injury can also be prevented experimentally by neutrophil-depleting mAb. 173 Antibodies which inhibit neutrophil adhesion may subsequently be shown to be important in the prevention of reperfusion injury following limb ischaemia, such as in abdominal aortic aneurysm surgery. 174 Undoubtedly, many more antibodies for use in the critically ill will emerge. Future clinical trials will require critical appraisal as the predicted world-wide expenditure associated with their use in 1994 is one billion US dollars. This figure is expected to rise to six billion US dollars by the end of the decade. 175 Rigorous criteria must also be developed to identify patients most likely to benefit from these new "drugs".
